IDH MUTATION
Clinical trials for IDH MUTATION explained in plain language.
Never miss a new study
Get alerted when new IDH MUTATION trials appear
Sign up with your email to follow new studies for IDH MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brain tumor combo shows promise in early trial
Disease control Recruiting nowThis study tests a combination of two drugs (ATRA and retifanlimab) in people with a specific type of brain tumor (IDH-mutant glioma) that has returned after standard treatment. The goal is to see if this combo can shrink tumors or slow their growth by helping the immune system a…
Matched conditions: IDH MUTATION
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New hope for bile duct cancer: drug may delay return after surgery and chemo
Disease control Recruiting nowThis study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…
Matched conditions: IDH MUTATION
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
Glioma Patients' voices heard: radiotherapy vs. new drug in Quality-of-Life showdown
Knowledge-focused Recruiting nowThis study listens to patients with a slow-growing brain tumor (IDH-mutant grade 2 glioma) to understand how they feel during treatment. It compares two approaches: radiotherapy and a drug called vorasidenib, plus a group just being watched. The goal is to learn which treatment b…
Matched conditions: IDH MUTATION
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 17, 2026 02:14 UTC
-
New drug targets brain tumors before surgery in early trial
Knowledge-focused Recruiting nowThis early study tests an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas (a type of brain tumor) who are scheduled for surgery. Participants take the drug for about 2 weeks before their tumor is removed. Researchers measure how much drug reaches the tumor and bloo…
Matched conditions: IDH MUTATION
Phase: EARLY_PHASE1 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:04 UTC